Imugene Valuation
| IUGNF Stock | USD 0.26 0.02 7.14% |
Imugene seems to be overvalued based on Macroaxis valuation methodology. Our model calculates the value of Imugene Limited from evaluating the firm fundamentals such as Return On Asset of -0.21, return on equity of -0.37, and Current Valuation of 737.79 M as well as inspecting its technical indicators and probability of bankruptcy.
Overvalued
Today
Please note that Imugene's price fluctuation is out of control at this time. Calculation of the real value of Imugene Limited is based on 3 months time horizon. Increasing Imugene's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the Imugene pink sheet is determined by what a typical buyer is willing to pay for full or partial control of Imugene Limited. Since Imugene is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Imugene Pink Sheet. However, Imugene's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 0.26 | Real 0.25 | Hype 0.26 | Naive 0.22 |
The real value of Imugene Pink Sheet, also known as its intrinsic value, is the underlying worth of Imugene Limited Company, which is reflected in its stock price. It is based on Imugene's financial performance, growth prospects, management team, or industry conditions. The intrinsic value of Imugene's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, or news.
Estimating the potential upside or downside of Imugene Limited helps investors to forecast how Imugene pink sheet's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Imugene more accurately as focusing exclusively on Imugene's fundamentals will not take into account other important factors: Imugene Total Value Analysis
Imugene Limited is currently estimated to have takeover price of 737.79 M with market capitalization of 642.17 M, debt of 673.43 K, and cash on hands of 99.89 M. Please note that takeover price may be misleading and is a subject to mistakes in financial statements. We encourage investors to thoroughly investigate all of the Imugene fundamentals before making investing decisions based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
737.79 M | 642.17 M | 673.43 K | 99.89 M |
Imugene Investor Information
About 15.0% of the company shares are held by company insiders. The company recorded a loss per share of 0.0. Imugene Limited had not issued any dividends in recent years. The entity had 2:15 split on the 12th of November 2002. Based on the measurements of operating efficiency obtained from Imugene's historical financial statements, Imugene Limited is not in a good financial situation at this time. It has a very high probability of going through financial hardship in August.Imugene Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Imugene has an asset utilization ratio of 8.79 percent. This implies that the Company is making $0.0879 for each dollar of assets. An increasing asset utilization means that Imugene Limited is more efficient with each dollar of assets it utilizes for everyday operations.Imugene Ownership Allocation
Imugene Limited has a total of 6.42 Billion outstanding shares. Imugene retains 15.4 (percent) of its outstanding shares held by insiders and 8.67 (percent) owned by outside corporations. Please note that no matter how many assets the company holds, if the real value of the firm is less than the current market value, you may not be able to make money on it.Imugene Profitability Analysis
The company reported the revenue of 12.97 M. Net Loss for the year was (37.87 M) with profit before overhead, payroll, taxes, and interest of 12.97 M.Please note that valuation analysis is one of the essential comprehensive assessments in business. It evaluates Imugene's worth, which you can determine by considering its current assets, liabilities and future cash flows. The investors' valuation analysis is an important metric that will give you a perspective on different companies. It helps you know the worth of the potential investment in Imugene and how it compares across the competition.
About Imugene Valuation
The pink sheet valuation mechanism determines Imugene's current worth on a weekly basis. Our valuation model uses a comparative analysis of Imugene. We calculate exposure to Imugene's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Imugene's related companies.Imugene Limited, a clinical stage immuno-oncology company, develops a range of immunotherapies to activate the immune system of cancer patients to treat and eradicate tumors in Australia. Imugene Limited was incorporated in 1986 and is based in Sydney, Australia. Imugene is traded on OTC Exchange in the United States.
8 Steps to conduct Imugene's Valuation Analysis
Company's valuation is the process of determining the worth of any company in monetary terms. It estimates Imugene's potential worth based on factors such as financial performance, market conditions, growth prospects, and overall economic environment. The result of company valuation is a single number representing a Company's current market value. This value can be used as a benchmark for various financial transactions such as mergers and acquisitions, initial public offerings (IPOs), or private equity investments. To conduct Imugene's valuation analysis, follow these 8 steps:- Gather financial information: Obtain Imugene's financial statements, including balance sheets, income statements, and cash flow statements.
- Determine Imugene's revenue streams: Identify Imugene's primary sources of revenue, including products or services offered, target markets, and pricing strategies.
- Analyze market data: Research Imugene's industry and market trends, including the size of the market, growth rate, and competition.
- Establish Imugene's growth potential: Evaluate Imugene's management, business model, and growth potential.
- Determine Imugene's financial performance: Analyze its financial statements to assess its historical performance and future potential.
- Choose a valuation method: Consider the Company's specific circumstances and choose an appropriate valuation method, such as the discounted cash flow (DCF) or comparable analysis method.
- Calculate the value: Apply the chosen valuation method to the financial information and market data to calculate Imugene's estimated value.
- Review and adjust: Review the results and make necessary adjustments, considering any relevant factors that may have been missed or overlooked.
Imugene Growth Indicators
Investing in growth stocks can be very risky. If the company such as Imugene does not do well, investors take a loss on the stock when it is time to sell. Also, because growth stocks typically do not pay dividends, the only opportunity an investor has to make money on their investment is when they eventually sell their shares.
| Common Stock Shares Outstanding | 5.9 B | |
| Retained Earnings | -103.5 M |
Complementary Tools for Imugene Pink Sheet analysis
When running Imugene's price analysis, check to measure Imugene's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Imugene is operating at the current time. Most of Imugene's value examination focuses on studying past and present price action to predict the probability of Imugene's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Imugene's price. Additionally, you may evaluate how the addition of Imugene to your portfolios can decrease your overall portfolio volatility.
| CEOs Directory Screen CEOs from public companies around the world | |
| Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
| Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals |